Giaquinto AN et al. Breast cancer statistics 2024. CA: A Cancer Journal for Clinicians. n/a(n/a).

Ganesh K, Massagué J. Targeting metastatic cancer. Nat Med. 2021;27(1):34–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Riggio AI, Varley KE, Welm AL. The lingering mysteries of metastatic recurrence in breast cancer. Br J Cancer. 2021;124(1):13–26.

Article  PubMed  Google Scholar 

Seale KN, Tkaczuk KHR. Circulating biomarkers in breast Cancer. Clin Breast Cancer. 2022;22(3):e319–31.

Article  CAS  PubMed  Google Scholar 

Welin M, et al. Structures of thymidine kinase 1 of human and mycoplasmic origin. Proc Natl Acad Sci. 2004;101(52):17970–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bello LJ. Regulation of thymidine kinase synthesis in human cells. Exp Cell Res. 1974;89(2):263–74.

Article  CAS  PubMed  Google Scholar 

Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem. 1988;263(17):8350–8.

Article  CAS  PubMed  Google Scholar 

Nisman B, et al. Serum thymidine kinase 1 activity in breast cancer. Cancer Biomark. 2010;7(2):65–72.

Article  CAS  PubMed  Google Scholar 

Nisman B, et al. Serum thymidine kinase 1 activity in the prognosis and monitoring of chemotherapy in lung cancer patients: a brief report. J Thorac Oncol. 2014;9(10):1568–72.

Article  CAS  PubMed  Google Scholar 

Stelmach P, et al. Prognostic value of thymidine kinase activity in patients with chronic lymphocytic leukemia. Postepy Hig Med Dosw (Online). 2016;70(0):1321–30.

PubMed  Google Scholar 

Nisman B, et al. Serum thymidine kinase 1 activity following nephrectomy for renal cell carcinoma and radiofrequency ablation of metastases to lung and liver. Anticancer Res. 2016;36(4):1791–7.

CAS  PubMed  Google Scholar 

Hanousková L et al. Thymidine Kinase-1 as additional diagnostic marker of prostate Cancer. Clin Lab, 2020. 66(6).

Mevizou R, Sirvent A, Roche S. Control of tyrosine kinase signalling by small adaptors in colorectal Cancer. Cancers (Basel), 2019. 11(5).

Costa Svedman F et al. Plasma thymidine kinase activity as a novel biomarker in metastatic melanoma patients treated with immune checkpoint inhibitors. Cancers (Basel), 2022. 14(3).

Weagel EG, et al. Biomarker analysis and clinical relevance of TK1 on the cell membrane of Burkitt’s lymphoma and acute lymphoblastic leukemia. Onco Targets Ther. 2017;10:4355–67.

Article  PubMed  PubMed Central  Google Scholar 

Murtola TJ, et al. Elevated levels of serum thymidine kinase 1 predict poor survival for patients with metastatic prostate Cancer. Eur Urol Open Sci. 2024;70:135–41.

Article  PubMed  PubMed Central  Google Scholar 

Di Raimondo F, et al. Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. Ann Oncol. 2001;12(5):621–5.

Article  PubMed  Google Scholar 

McCartney A, Malorni L. Potential through simplicity: thymidine kinase-1 as a biomarker for CDK4/6 inhibitors. Br J Cancer. 2020;123(2):176–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bagegni N, et al. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 Inhibition in patients with early-stage breast cancer receiving neoadjuvant Palbociclib. Breast Cancer Res. 2017;19(1):123.

Article  PubMed  PubMed Central  Google Scholar 

Alegre MM, Robison RA. and K.L. O’Neill, Thymidine kinase 1 upregulation is an early event in breast tumor formation. J Oncol, 2012. 2012: p. 575647.

Nisman B, et al. Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients. Clin Chem Lab Med (CCLM). 2013;51(2):439–47.

Article  CAS  PubMed  Google Scholar 

Fanelli GN et al. Immunohistochemistry for thymidine Kinase-1 (TK1): A potential tool for the prognostic stratification of breast Cancer patients. J Clin Med, 2021. 10(22).

Hussein A, Baban R. Evaluation of thymidine Kinase-1 as a potential biomarker and its association with CA 15– 3 in patients with non-metastatic breast cancer. NeuroQuantology. 2022;20:5943–51.

Google Scholar 

Ma CX, et al. NeoPalAna: neoadjuvant Palbociclib, a Cyclin-Dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 Estrogen Receptor-Positive breast Cancer. Clin Cancer Res. 2017;23(15):4055–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu Y, et al. The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial. Breast Cancer Res Treat. 2024;204(2):299–308.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang HJ, Kennedy BJ, Kiang DT. Thymidine kinase as a predictor of response to chemotherapy in advanced breast cancer. Breast Cancer Res Treat. 1984;4(3):221–5.

Article  CAS  PubMed  Google Scholar 

Mehta Rita S et al. Combination anastrozole and fulvestrant in metastatic breast Cancer. N Engl J Med 367(5): pp. 435–44.

Paoletti C, et al. Evaluating serum thymidine kinase 1 in patients with hormone Receptor–Positive metastatic breast Cancer receiving First-line endocrine therapy in the SWOG S0226 trial. Clinical Cancer Research; 2021.

Krishnamurthy J, et al. A phase II trial of an alternative schedule of Palbociclib and embedded serum TK1 analysis. NPJ Breast Cancer. 2022;8(1):35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cabel L, et al. Plasma thymidine kinase 1 activity and outcome of ER + HER2– metastatic breast cancer patients treated with Palbociclib and endocrine therapy. Breast Cancer Res. 2020;22(1):1–9.

Article  Google Scholar 

Albanell J, et al. Randomized phase II study of fulvestrant plus Palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER). Eur J Cancer. 2022;161:26–37.

Article  CAS  PubMed  Google Scholar 

Albanell J, et al. Use of liquid biomarker thymidine kinase activity (TKa) to predict outcome and progression in patients with metastatic breast cancer (MBC) in the GEICAM/2014-12 FLIPPER trial. J Clin Oncol. 2024;42(16suppl):1028–1028.

Article  Google Scholar 

Malorni L, et al. Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: results from the prospective bioitalee trial. Eur J Cancer. 2023;186:1–11.

Article  CAS  PubMed  Google Scholar 

Bjöhle J, et al. Serum thymidine kinase activity compared with CA 15– 3 in locally advanced and metastatic breast cancer within a randomized trial. Breast Cancer Res Treat. 2013;139(3):751–8.

Article  PubMed  Google Scholar 

Bonechi M, et al. Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy. Oncotarget. 2018;9(23):16389–99.

Article  PubMed  PubMed Central  Google Scholar 

McCartney A, et al. Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: analysis of the randomised phase III evaluation of Faslodex versus exemestane clinical trial (EFECT). Eur J Cancer. 2019;114:55–66.

Article  CAS  PubMed  Google Scholar 

McCartney A, et al. Plasma thymidine kinase activity as a biomarker in patients with luminal metastatic breast Cancer treated with Palbociclib within the trend TrialPlasma thymidine kinase activity and Palbociclib treatment. Clin Cancer Res. 2020;26(9):2131–9.

Article  CAS  PubMed  Google Scholar 

Malorni L, et al. Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with Palbociclib and fulvestrant. Eur J Cancer. 2022;164:39–51.

Article  CAS  PubMed  Google Scholar 

Kalinsky K, et al. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on Cyclin-Dependent kinase 4/6 Inhibition in hormone receptor–Positive, human epidermal growth factor receptor 2–Negative metastatic breast cancer: MAINTAIN trial. J Clin Oncol. 2023;41(24):4004–13.

Article  CAS  PubMed